Loading stock data…
MYO
$1.31+0.03 (+2.34%)
After Hours$1.37+0.06 (+4.58%)· Last close Jun 9
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Myomo, Inc. in the Healthcare sector is trading at $1.31. Wall Street consensus targets $4.42 (5 analysts), implying a +237.4% move over the next 12 months. The stock is currently 56% below its 52-week high of $2.99, remaining 45.6% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +237.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$1.31
Potential Downside
0%
Whystock Fair Value$1.31
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled up...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-167.95%
Volume
Today's trading volume
895,256
Recent News
Undervalued Penny Stocks To Consider In June 2026
Over the last 7 days, the United States market has dropped 2.5%, but it remains up 23% over the past year with earnings forecasted to grow by 17% annually. For investors looking beyond well-known stocks, penny stocks—often representing smaller or newer companies—can present intriguing opportunities despite their somewhat outdated label. By focusing on those with strong financial health and potential for growth, investors might uncover valuable options in this niche area of the market.
Myomo (MYO) Shows Fast-paced Momentum But Is Still a Bargain Stock
Myomo (MYO) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Here Is Why Bargain Hunters Would Love Fast-paced Mover Myomo (MYO)
Myomo (MYO) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Myomo, Inc. Q1 2026 Earnings Call Summary
Moby summary of Myomo, Inc.'s Q1 2026 earnings call
Myomo, Inc. (MYO) Reports Q1 Loss, Beats Revenue Estimates
Myomo (MYO) delivered earnings and revenue surprises of +21.74% and +8.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?